Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus

Annals of Pharmacotherapy

Volumn 48, Issue 9, 2014, Pages 1202-1208

  Aylsworth, Andrew ^a   Dean, Zachary ^a   VanNorman, Cody ^a   Nkemdirim Okere, Arinze ^a  

^a FERRIS STATE UNIVERSITY   (United States)

Author keywords

dapagliflozin; Farxiga; SGLT 2 inhibitor

Indexed keywords

ANTIDIABETIC AGENT; DAPAGLIFLOZIN; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SITAGLIPTIN;

ADD ON THERAPY; ADVERSE DRUG REACTION; AREA UNDER THE CURVE; CARDIOVASCULAR RISK; DEHYDRATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; GENITAL TRACT INFECTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INFECTION RISK; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MONOTHERAPY; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHARMACODYNAMICS; PHARMACOKINETICS; PHARMACOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UNITED STATES; URINARY EXCRETION; URINARY TRACT INFECTION;

EID: 84905458974     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014540450     Document Type: Review

References (23)

1. Danaei G,Finucane MM,Lu Y, et al.National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants.Lancet. 2011;378:31-40.
2. Diabetes Care. 2014;37:5-13.
3. Princeton, NJ: Bristol-Myers Squibb Company; 2014:.
4. Triplitt CL,Repas T,Alvarez CPharmacotherapy: A Pathophysiologic Approach. 9th ed.New York, NY: McGraw-Hill; 2014:1143-1190.DiPiro JTTalbert RLYee GCMatzke GRWells BGPosey LM, ed. New York, NY: McGraw-Hill; 1143-1190.
5. Hudson, OH: Lexicomp.
6. Kasichayanula S,Liu X,Lacreta F,Griffen SC,Boulton DW.Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.Clin Pharmacokinet. 2014;53:17-27.
7. Ferrannini E,Ramos SJ,Salsali A,Tang W,List JF.Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.Diabetes Care. 2010;33:2217-2224.
8. Bailey CJ,Iqbal N,T'joen C,List JF.Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.Diabetes Obes Metab. 2012;14:951-959.
9. Henry RR,Murray AV,Marmolejo MH,Hennicken D,Ptaszynska A,List JF.Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomized controlled trial.Int J Clin Pract. 2012;66:446-456.
10. Bailey CJ,Gross JL,Hennicken D,Iqbal N,Mansfield TA,List JF.Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.BMC Med. 2013;11:43.
11. Strojek K,Yoon KH,Hruba V,Elze M,Langkilde AM,Parikh S.Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.Diabetes Obes Metab. 2011;13:928-938.
12. Nauck MA,Del Prato S,Meier JJ, et al.Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.Diabetes Care. 2011;34:2015-2022.
13. Wilding JP,Norwood P,T'joen C,Bastien A,List JF,Fiedorek FT.A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.Diabetes Care. 2009;32:1656-1662.
14. Rosenstock J,Vico M,Wei L,Salsali A,List JF.Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.Diabetes Care. 2012;35:1473-1478.
15. Jabbour SA,Hardy E,Sugg J,Parikh S, et al.Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.Diabetes Care. 2014;37:740-750.
16. Liu JJ,Lee T,DeFronzo RA.Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?.Diabetes. 2012;61:2199-2204.
17. Zhang M,Zhang L,Wu B,Song H,An Z,Li S.Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.Diabetes Metab Res Rev. 2014;30:204-221.
18. Food and Drug Administration. FDA Briefing Document NDA 202293. Dapagliflozin 5 and 10 mg. 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262994.pdf. Accessed June 4, 2014.
19. Riser Taylor S,Harris KB.The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.Pharmacotherapy. 2013;33:984-999.
20. Matthews DR,Fulcher G,Perkovic V, et al.Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy +/- oral agents in type 2 diabetes.Diabetologia. 2012;55:S314-S315.
21. Med Lett Drugs Ther. 2014;56 (1436): 13-14.
22. Greenwood Village, CO: Truven Health Analytics, Inc. Updated periodically;.
23. Garber AJ,Abrahamson MJ,Barzilay JI, et al.American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement-executive summary.Endocr Pract. 2013;19:536-557.